TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06554223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUSTAIN-DSD
Description: Participants randomized to SUSTAIN-DSD will be enrolled into an Adherence Club and will have 6 months of ART dispensed through a pre-packed dispensing service. Participants may choose to use the decentralized pick-up point solely for medication retrieval or may opt into the peer-support aspect of the Clubs by attending the group session of up to 30 PWH, who will meet once every 6 months in a safe space (e.g., clinic meeting room, church, or local library).~At 6 months, 12 months, and every 12 months thereafter, a visiting nurse will draw a blood specimen for viral load. Optional process uptake will be recorded. Participants with a raised viral load will be called and offered enhanced adherence counselling; then recalled for a repeat viral load in 3 months.
Study: NCT06708143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal Interference
Description: Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of drug resistant epilepsy patients.
Study: NCT06710197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®)
Description: 100 mg/daily subcutaneously
Study: NCT06708845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zamtocabtagene autoleucel
Description: chimeric antigen receptor T-cell (CAR-T) therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zamtocabtagene autoleucel
Description: chimeric antigen receptor T-cell (CAR-T) therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study: NCT06709586

Intervention type: PROCEDURE
Intervention: Thermal ablation
Description: Thermal ablation is a treatment for secondary hyperparathyroidism. There are radiofrequency ablation (RFA) and microwave ablation (MWA). For RFA, an electrode needle is inserted into the parathyroid under imaging guidance. High - frequency current heats the tissue to cause necrosis. MWA uses electromagnetic waves to generate heat by friction. Before ablation, imaging and lab tests are done for evaluation. During the process, precise positioning and real - time monitoring are key. After that, patients are observed for bleeding, swelling and other symptoms, and tests are repeated to assess the effect.

Intervention type: PROCEDURE
Intervention: parathyroidectomy
Description: Parathyroidectomy for secondary hyperparathyroidism is a common approach. The surgeon first makes an incision in the neck area under general or local anesthesia. Then, the enlarged parathyroid glands are carefully identified and dissected. Precise surgical skills are required to avoid damaging nearby structures such as the recurrent laryngeal nerve and blood vessels. After the removal of the abnormal parathyroid tissue, the wound is closed.
Study: NCT06710704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous pulsed radiofrequency
Description: Patients underwent transcutaneous PRF at the affected elbow.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone and mepacaine
Description: Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
Study: NCT06707493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib tablets are supplied as 50 mg, 200 mg, and 250 mg strengths, to be taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are taken orally.
Study: NCT06707311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received calcium hydroxide with glass ionomer restorative material
Description: patients received calcium hydroxide with glass ionomer restorative material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received TheraCal LC with glass ionomer restorative material
Description: patients received TheraCal LC with glass ionomer restorative material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received bioactive bonding with glass ionomer restorative material
Description: patients received bioactive bonding with glass ionomer restorative material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received universal bonding with glass ionomer restorative material
Description: patients received bioactive bonding with glass ionomer restorative material
Study: NCT06710353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: A 20% albumin solution is administered over one hour starting from the induction of anesthesia, using the following formula:~(4.0-preoperative serum albumin (g/dL))×plasma volume (kg×0.65-0.8 dL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid solutions
Description: The same volume of crystalloid solution as the administered albumin is infused.
Study: NCT06373250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Membrane stripping group
Description: An information form will be filled in for admission to the Primipar participating maternity unit. Membrane stripping will be performed during a vaginal examination at least once during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: You will be asked to fill in an information form to be admitted to the Primipar participating maternity unit. No membrane stripping are applied and no cervical interventions are made during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the VAS and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
Study: NCT06710808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual walking and transcranial direct current stimulation
Description: Participants will receive VW-therapy combined with tDCS. The intervention is adapted from Soler et al. 2010 and consists of 10 sessions over 2 weeks, each session lasting around 20 minutes.~For the virtual walking the participant sits on a modified wheelchair, which is positioned at a distance of two meters from the screen. The setting provides an illusion of a third person perspective and the participant can see himself/herself walk through a forest ambience.~The tDCS session is according the same protocol from Soler et al., 2010. Hereby, the device from Starstim, Neuroelectrics will be used, which is equipped with a neoprene cap containing electrodes. The anodes will be placed over C3 or C4 (EEG 10/20 system) to target the motor cortex (M1) contralateral to the painful side and the cathodes will be placed over the contralateral supraorbital area. Symmetric pain participants receive stimulation on the dominant hemisphere. The tDCS applies a constant current of 2 mA over 20 minutes.
Study: NCT06710002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvify: Menopause and dyspareunia treatment
Description: Topics addressed in the Asynchronous Online Telerehabilitation Program would be:~1. What it is and why it hurts during sex. What is dyspareunia?~2. How to recover vaginal elasticity.~3. Massage~4. Self-palpation.~5. Stretching of the pelvic floor muscles.~6. Use of vaginal dilators.~7. Moisturizers and lubricants.~8. Sexual pleasure.~9. Communication with the partner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face Physical Therapy Protocol
Description: Physical Therapy Protocol will be based on:~1. Health education:~2. CMRF: INDIBA® ACTIV CT8 will be used to apply the radiofrequency~3. Manual therapy: it will be based on performing the Thiele's massage.~4. Vaginal dilators: FEMINAFORM® vaginal dilators will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face Protocol Combined With an Asynchronous Telerehabilitation Program
Description: Both, the face to face protocol and the Asynchronous Telerehabilitation Program will be carried on on this group.
Study: NCT06554223

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced (guideline-driven) Standard of Care (E-SoC)
Description: As per current SA ART guidelines, all patients who are \>28 days late for a scheduled visit are offered enhanced adherence counselling (EAC) at reengagement and restarted on ART. Patients who are \>90 days late also have blood drawn for a CD4 count to test for advanced HIV disease. Individual clinic visits occur every 3 months, with 3-month ART dispensing. VL testing is repeated 3 months after restart, then at 12 months and annually there-after, if suppressed.~These visits will be managed by clinic staff (nurse or doctor). EAC is a single counselling session delivered by a lay counsellor.~The study team will ensure all SoC processes are complete as per the guidelines; and reported to the COCT team as appropriate.
Study: NCT06710262

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS PL Assay
Description: The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS PL Assay
Description: The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS PL Assay
Description: The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS PL Assay
Description: The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function
Study: NCT06710145

Intervention type: BEHAVIORAL
Intervention: Combat Attention Training
Description: The Combat Attention App is a response-time based mechanized preventive intervention designed to train combat soldiers' attention toward threats before combat exposure in order to reduce the risk for combat-related post-trauma symptoms. In light of the results of controlled studies that proved the efficacy of this preventive intervention, the Israel Defense Forces (IDF) decided at the beginning of the Iron Swords War (October 7th, 2023) to implement an internet-based App of the intervention, and soldiers and combat reservists were invited to train on the Combat Attention App.
Study: NCT06708806

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (XY1) vs. an toric IOL (XY1A)
Study: NCT06707415

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials
Description: Auditory evoked potentials in parallel systems
Study: NCT06707194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Prefilled syringe, 25mg of hypodermic injection, twice a week

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Prefilled syringe, 25mg of hypodermic injection, twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin
Description: Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzathine Penicillin
Description: Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, intramuscular injection, once every two weeks
Study: NCT06735534

Intervention type: DEVICE
Group type: OTHER
Intervention: FARAPULSE™ Pulsed Field Ablation System
Description: The FARAPULSE™ Pulsed Field Ablation System is indicated for the treatment of symptomatic atrial fibrillation.~The FARAWAVE Catheter is indicated for the isolation of pulmonary veins and posterior wall in the treatment of drug-refractory, recurrent, symptomatic paroxysmal and persistent atrial fibrillation. The FARAWAVE Catheter is also indicated for the for the isolation of pulmonary veins and posterior wall in the treatment of persistent atrial fibrillation as an alternative to anti-arrhythmic drug (AAD) therapy as an initial rhythm control strategy.~The FARAPOINT™ PFA Catheter is indicated for use as an adjunctive device for 1) the creation of an ablation line between the inferior vena cava and the tricuspid valve and/or 2) Mitral Isthmus, when the FARAWAVE Catheter is used in the endocardial treatment of persistent atrial fibrillation (episode duration no greater than 12 months).
Study: NCT06745661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLRL device
Description: Each participant in the intervention group will be provided a repeated low-level red-light therapy (RLRL) device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham device
Description: Each participant in the sham group will be provided a sham therapy device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
Study: NCT05983198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-R2
Description: PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-R2
Description: PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-R2
Description: PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-R2
Description: Kit for radiopharmaceutical preparation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-R2
Description: Kit for radiopharmaceutical preparation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-R2
Description: Kit for radiopharmaceutical preparation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Kit for radiopharmaceutical preparation
Study: NCT05212194

Intervention type: OTHER
Group type: OTHER
Intervention: examination
Description: Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
Study: NCT05983198

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Kit for radiopharmaceutical preparation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Kit for radiopharmaceutical preparation
Study: NCT04914923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse
Description: Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
Study: NCT04897503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
Study: NCT05314595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral uterine artery ligation
Description: * Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss.
Study: NCT06637839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Locomotor Training Program
Description: The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
Study: NCT04611126

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamid
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamid
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study: NCT06637839

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Step Count Locomotor Training Program
Description: The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
Study: NCT06642233

Intervention type: DIAGNOSTIC_TEST
Intervention: Socio-demographic survey
Description: Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.

Intervention type: DIAGNOSTIC_TEST
Intervention: The World Health Organization Quality-of-Life Scale-BREF questionnaire
Description: The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).

Intervention type: DIAGNOSTIC_TEST
Intervention: The International Physical Activity Questionnaire
Description: The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
Study: NCT04611126

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine Phosphate
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine Phosphate
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tumor Infiltrating Lymphocytes infusion
Description: Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tumor Infiltrating Lymphocytes infusion
Description: Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
Study: NCT04914923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Description: Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular